Portal de Periódicos da CAPES

Routine drug and food interactions during antihelminthic treatment of neurocysticercosis: A reason for the variable efficacy of albendazole and praziquantel?

2014; Wiley; Volume: 54; Issue: 4 Linguagem: Inglês

10.1002/jcph.269

1552-4604

Matthew L. Romo, Arturo Carpio, Elizabeth A. Kelvin,

Parasites and Host Interactions

The Journal of Clinical PharmacologyVolume 54, Issue 4 p. 361-367 Continuing Education Routine drug and food interactions during antihelminthic treatment of neurocysticercosis: A reason for the variable efficacy of albendazole and praziquantel? Matthew L. Romo PharmD, Corresponding Author Matthew L. Romo PharmD CUNY School of Public Health, New York, NY, USA Corresponding Author: Matthew L. Romo, PharmD, Department of Epidemiology and Biostatistics, CUNY School of Public Health, 2180 Third Avenue, New York, NY 10035, USA Email: matthew.l.romo@gmail.comSearch for more papers by this authorArturo Carpio MD, Arturo Carpio MD School of Medicine, University of Cuenca, Cuenca, Ecuador GH Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USASearch for more papers by this authorElizabeth A. Kelvin PhD, MPH, Elizabeth A. Kelvin PhD, MPH CUNY School of Public Health, New York, NY, USASearch for more papers by this author Matthew L. Romo PharmD, Corresponding Author Matthew L. Romo PharmD CUNY School of Public Health, New York, NY, USA Corresponding Author: Matthew L. Romo, PharmD, Department of Epidemiology and Biostatistics, CUNY School of Public Health, 2180 Third Avenue, New York, NY 10035, USA Email: matthew.l.romo@gmail.comSearch for more papers by this authorArturo Carpio MD, Arturo Carpio MD School of Medicine, University of Cuenca, Cuenca, Ecuador GH Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York, NY, USASearch for more papers by this authorElizabeth A. Kelvin PhD, MPH, Elizabeth A. Kelvin PhD, MPH CUNY School of Public Health, New York, NY, USASearch for more papers by this author First published: 20 January 2014 https://doi.org/10.1002/jcph.269Citations: 10Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Abstract Neurocysticercosis (NC) or infection of the central nervous system with Taenia solium larvae is a leading cause of preventable seizures and epilepsy in endemic regions across the globe. Albendazole and praziquantel are commonly used antihelminthic agents to treat NC; however, viable cysts persist in the majority of patients, putting them at risk for future seizures and other neurological complications. Because of their pharmacokinetic profiles, albendazole and praziquantel have the potential to interact with many different drugs. During antihelminthic treatment, antiepileptic drugs and corticosteroids are commonly co-administered to manage seizures and cerebral edema; however, the most commonly used agents from these drug classes are known to significantly alter plasma concentrations of albendazole and praziquantel. The overarching issue with drug interactions during the treatment of NC is whether or not they have clinical relevance, as the plasma concentrations of albendazole and praziquantel have not been directly linked with eradication of viable cysts. Future studies should attempt to evaluate the validity of a causal relationship between antihelminthic plasma concentrations and outcomes so that drug interactions can be better understood and managed and so that treatment can be optimized. Citing Literature Volume54, Issue4April 2014Pages 361-367 RelatedInformation